Citations

Clear

941 citation(s) found for "Tefferi, A".

The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
Mudireddy, Mythri , Barraco, Daniela , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | February 17, 2017 | Volume: 92 | Issue: 5 | Pages: 454-459

10.1002/ajh.24689 | PMID 28211153 Get It

AbstractThe 2016 World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (MPN) underscore the prognostically‐relevant distinction between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre‐PMF). In addition, leukocytosis has been identified as an important prognostic marker in otherwise WHO‐defined ET. However, controversy remains regarding the objectivity of morphologic criteria in distinguishing ET from pre‐PMF and the precise prognostic cutoff values for leukocytosis. Serum lactate dehydrogenase (LDH) level might be a biologically more accurate measure of leukocyte turnover and a more sensitive marker of pre‐PMF, in otherwise WHO‐defined ET. In the current study of 183 consecutive patients with WHO‐defined ET, the presence of grade 1 bone marrow (BM) fibrosis did not affect presenting clinical or laboratory features; in contrast, increased serum LDH at diagnosis was associated with leukocytosis (p = .002), thrombocytosis (p < .001), palpable splenomegaly (p = .03) and higher international prognostic score (IPSET) (p = .002); serum LDH did not correlate with BM fibrosis, JAK2/CALR/MPL or TET2/ASXL1 mutations. In univariate analysis, risk factors for survival included age ≥60 years (p = .002; HR 10.2, 95% CI 2.3‐44.6), male sex (p = .02; HR 3.2, 95% CI 1.2‐8.2), leukocyte count ≥15 × 109/L (p = .007; HR 4.7, 95% CI 1.5‐14.6), and increased serum LDH (p = .002; HR 3.7, 95% CI 1.5‐9.1), but not BM fibrosis (p = .17). In multivariable analysis, age, sex and serum LDH remained significant; serum LDH also remained significant, in the context of IPSET (p = .003) and in patients with leukocytosis (p = .003). We conclude that serum LDH level carries an independent prognostic value for survival in ET and might represent a biologically more accurate surrogate for leukocytosis.
Diagnostic impact of the 2016 revised who criteria for polycythemia vera
Barbui, Tiziano , Thiele, Jüergen, Gisslinger, Heinz , Carobbio, Alessandra , Tefferi, Ayalew , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | February 14, 2017 | Volume: 92 | Issue: 5 | Pages: 417-419

10.1002/ajh.24684 | PMID 28196400 Get It

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS‐T): 2017 update on diagnosis, risk‐stratification, and management
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | February 11, 2017 | Volume: 92 | Issue: 3 | Pages: 297-310

10.1002/ajh.24637 | PMID 28188970 Get It

AbstractDisease OverviewRing sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T).DiagnosisMDS‐RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN‐RS‐T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS‐RS‐SLD, along with a platelet count ≥ 450 × 10(9)/L and large atypical megakaryocytes (similar to BCR‐ABL1 negative MPN).Mutations and KaryotypeMutations in SF3B1 are seen in ≥80% of patients with MDS‐RS‐SLD and MDS/MPN‐RS‐T, and strongly correlate with the presence of BM RS; MDS/MPN‐RS‐T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations; with ASXL1/SETBP1 mutations adversely impacting survival. Cytogenetic abnormalities are uncommon in both diseases.Risk stratificationMost patients with MDS‐RS‐SLD are stratified into lower risk groups by the revised‐International Prognostic Scoring System (R‐IPSS). Disease outcome in MDS/MPN‐RS‐T is better than that of MDS‐RS‐SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemicTreatmentAnemia and iron overload are complications seen in both and are managed similar to lower risk MDS and MPN. Aspirin therapy is reasonable in MDS/MPN‐RS‐T, especially in the presence of JAK2V617F, but the value of platelet‐lowering drugs is uncertain.
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, Ayalew , Barbui, Tiziano, Barbui, Tiziano

Mayo Clinic

American Journal of Hematology | December 19, 2016 | Volume: 92 | Issue: 1 | Pages: 94-108

10.1002/ajh.24607 | PMID 27991718 Get It

AbstractDisease overviewPolycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation.DiagnosisPV is defined by aJAK2mutation, whose absence, combined with normal or increased serum erythropoietin level, makes the diagnosis unlikely.JAK2,CALR, andMPLmutations are the mutually exclusive “driver” mutations in ET with respective incidences of 55%, 25%, and 3%; approximately 17% are triple‐negative. However, the same molecular markers might also be present in prefibrotic myelofibrosis, whose morphological distinction from ET is prognostically relevant.Survival and leukemic/fibrotic transformationMedian survivals are approximately 14 years for PV and 20 years for ET; the corresponding values for younger patients (age <60 years) are 24 and 33 years. Life‐expectancy in ET is inferior to the control population. Driver mutational status has not been shown to affect survival in ET whereas the presence ofJAK2/MPLmutations has been associated with higher risk of arterial thrombosis and that ofMPLwith higher risk of fibrotic progression. Risk factors for overall survival in both ET and PV include advanced age, leukocytosis and thrombosis. Leukemic transformation rates at 20 years are estimated at <10% for PV and 5% for ET; fibrotic transformation rates are slightly higher. Most recently,ASXL1,SRSF2, andIDH2mutations have been associated with inferior overall, leukemia‐free or fibrosis‐free survival in PV; similarly adverse mutations in ET includedSH2B3,SF3B1,U2AF1,TP53,IDH2, andEZH2.Thrombosis risk stratificationCurrent risk stratification in PV and ET is designed to estimate the likelihood of recurrent thrombosis. Accordingly, PV includes two risk categories: high‐risk (age >60 years or thrombosis history) and low‐risk (absence of both risk factors). In ET, risk stratification includes four categories: very low risk (age ≤60 years, no thrombosis history,JAK2/MPLun‐mutated), low risk (age ≤60 years, no thrombosis history,JAK2/MPLmutated), intermediate risk (age >60 years, no thrombosis history,JAK2/MPLun‐mutated), and high risk (thrombosis historyorage >60 years withJAK2/MPLmutation). In addition, presence of extreme thrombocytosis (platelets >1000 × 10(9)/L) might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding.Risk‐adapted therapyThe main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once‐daily aspirin (81 mg). In addition, high‐risk patients with PV require cytoreductive therapy. Very low risk ET patients might not require any form of therapy while low‐risk patients require at least once‐daily aspirin therapy. Cytoreductive therapy is also recommended for high‐risk ET patients but it is not mandatory for intermediate‐risk patients. First‐line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second‐line drugs of choice are interferon‐α and busulfan. We currently do not recommend treatment with ruxolutinib or otherJAK2inhibitors in PV or ET, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs. Screening for AvWS is recommended before administrating aspirin, in the presence of extreme thrombocytosis. Am. J. Hematol. 92:95–108, 2017. © 2016 Wiley Periodicals, Inc.
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, Ayalew , Finke, Christy M. , Rotunno, Giada, Elala, Yoseph, Pacilli, Annalisa , Hanson, Curtis A. , Pancrazzi, Alessandro , Mannarelli, Carmela, Barraco, Daniela , Fanelli, Tiziana , Pardanani, Animesh , Gangat, Naseema , Lasho, Terra L. , Guglielmelli, Paola , Ketterling, Rhett P. , Vannucchi, Alessandro M.

Mayo Clinic

Blood Advances | November 30, 2016 | Volume: 1 | Issue: 1 | Pages: 21-30

10.1182/bloodadvances.2016000216 | PMID 29296692 Get It

Key Points More than half of patients with PV or ET harbor DNA mutations/variants other than JAK2/CALR/MPL. The presence of some of these mutations adversely affects overall, leukemia-free, or myelofibrosis-free survival.
Targeted deep sequencing in primary myelofibrosis
Tefferi, Ayalew , Finke, Christy M. , Elala, Yoseph, Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Ketterling, Rhett P.

Mayo Clinic

Blood Advances | November 30, 2016 | Volume: 1 | Issue: 2 | Pages: 105-111

10.1182/bloodadvances.2016000208 | PMID 29296803 Get It

Key Points More than 80% of patients with PMF harbor DNA variants/mutations other than JAK2/CALR/MPL. Some of these variants/mutations adversely affect overall or leukemia-free survival independent of conventional risk stratification.
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | November 17, 2016 | Volume: 91 | Issue: 12 | Pages: 1262-1271

10.1002/ajh.24592 | PMID 27870387 Get It

Disease overview:Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied byJAK2,CALRorMPLmutation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression and shortened survival.Diagnosis:Diagnosis is based on bone marrow morphology. The presence ofJAK2,CALRorMPLmutation is supportive but not essential for diagnosis; approximately 90% of patients carry one of these mutations and 10% are “triple‐negative.” None of these mutations are specific to PMF and are also seen in essential thrombocythemia (ET). According to the revised 2016 World Health Organization (WHO) classification and diagnostic criteria, “prefibrotic” PMF (pre‐PMF) is distinguished from “overtly fibrotic” PMF; the former might mimic ET in its presentation and it is prognostically relevant to distinguish the two.Risk stratification:The Dynamic International Prognostic Scoring System‐plus (DIPSS‐plus)uses eight predictors of inferior survival: age >65 years, hemoglobin <10 g/dL, leukocytes >25 × 109/L, circulating blasts ≥1%, constitutional symptoms, red cell transfusion dependency, platelet count <100 × 109/L and unfavorable karyotype (i.e., complex karyotype or sole or two abnormalities that include +8, −7/7q‐, i(17q), inv(3), 5/5q‐, 12p‐, or 11q23 rearrangement). The presence of 0, 1, “2 or 3” and ≥4 adverse factors defines low, intermediate‐1, intermediate‐2 and high‐risk disease with median survivals of approximately 15.4, 6.5, 2.9 and 1.3 years, respectively. Most recently, DIPSS‐plus‐independent adverse prognostic relevance has been demonstrated for certain mutations includingASXL1andSRSF2whereas patients with type 1/likeCALRmutations, compared to their counterparts with other driver mutations, displayed significantly better survival.Risk‐adapted therapy:Observation alone is a reasonable treatment strategy for asymptomaticloworintermediate‐1DIPSS‐plus risk disease, especially in the absence of high‐risk mutations. All other patients withhighorintermediate‐2 riskdisease, or those harboring high‐risk mutations such asASXL1orSRSF2, should be considered for stem cell transplant, which is currently the only treatment modality with the potential to favorably modify the natural history of the disease. Non‐transplant candidates should be encouraged to participate in clinical trials, since the value of conventional drug therapy, including the use of JAK2 inhibitors, is limited to symptoms palliation and reduction in spleen size. Specifically, JAK2 inhibitors have not been shown to induce complete clinical or cytogenetic remissions or significantly affectJAK2/CALR/MPLmutant allele burden. Splenectomy is considered for drug‐refractory splenomegaly. Involved field radiotherapy is most useful for post‐splenectomy hepatomegaly, non‐hepatosplenic EMH, PMF‐associated pulmonary hypertension and extremity bone pain. Am. J. Hematol. 91:1262–1271, 2016. © 2016 Wiley Periodicals, Inc.
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia
Barraco, Daniela , Finke, Christy M. , Ketterling, Rhett P. , Gangat, Naseema , Hanson, Curtis A. , Tefferi, Ayalew , Patnaik, Mrinal M. , Zahid, Mohammad Faizan, Lasho, Terra L. , Zahid, Mohammad Faizan , Ketterling, Rhett P

Mayo Clinic

Leukemia & Lymphoma | October 14, 2016 | Volume: 58 | Issue: 6 | Pages: 1488-1493

10.1080/10428194.2016.1243681 | PMID 27739921 Get It

The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
Barbui, Tiziano , Carobbio, Alessandra , Rumi, Elisa , Gisslinger, Heinz , Ruggeri, Marco , Randi, Maria Luigia , Rambaldi, Alessandro , Gisslinger, Bettina, Pieri, Lisa , Thiele, Jüergen, Pardanani, Animesh , Tefferi, Ayalew , Vannucchi, Alessandro M. , Finazzi, Guido , Cazzola, Mario , Rambaldi, Alessandro

Mayo Clinic

American Journal of Hematology | October 14, 2016 | Volume: 92 | Issue: 1 | Pages: No page available

10.1002/ajh.24583 | PMID 27737508 Get It

DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia
Patnaik, Mrinal M. , Barraco, Daniela , Finke, Christy M. , Hanson, Curtis A. , Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | October 13, 2016 | Volume: 92 | Issue: 1 | Pages: 56-61

10.1002/ajh.24581 | PMID 27733013 Get It

DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n = 261). DNMT3A mutations were seen in 6% (n = 16); 56% (n = 9) male, with a median age of 64 years. Eighty‐one % of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes. Five (31%) patients had an abnormal karyotype whereas concurrent gene mutations (SF3B1/SRSF2/U2AF1−56%, TET2−50%, and ASXL1−25%) were seen in all patients. Apart from a higher frequency of SF3B1 (P = 0.0001) and PTPN11 (P = 0.005) mutations and a lower frequency of SRSF2 (P = 0.004) mutations, there were no significant differences between DNMT3A mutated patients and their wildtype counterparts. In univariate analysis, survival was shorter in DNMT3A mutated (median 8 months) versus wildtype (median 27 months) patients (P = 0.0007; HR 2.9, 95% CI 1.5–5.7); with other variables of significance including lower hemoglobin (P = 0.002), higher leukocyte count (P = 0.0009), higher monocyte count (P = 0.0012), circulating blast % (P = 0.001), circulating immature myeloid cells (P = 0.01), bone marrow blast % (P = 0.045), abnormal karyotype (P = 0.02), and ASXL1 (P = 0.01) mutations. In a multivariable model that included the aforementioned variables, when both DNMT3A and ASXL1 mutations were added, only DNMT3A (P < 0.0001) and ASXL1 (P = 0.004) mutations remained significant. DNMT3A mutations were also predictive of a shortened leukemia‐free survival. These findings warrant inclusion of DNMT3A mutations in molecularly integrated CMML prognostic models. Am. J. Hematol. 92:56–61, 2017. © 2016 Wiley Periodicals, Inc.